UK VC firm launch­es strate­gic re­view, pon­ders shut­down

Ar­ix Bio­science is con­duct­ing a strate­gic re­view that could in­clude wind­ing down the UK-based ven­ture cap­i­tal firm.

Ar­ix said it is eval­u­at­ing its in­vest­ment strate­gies and its poli­cies around al­lo­cat­ing cap­i­tal and re­turns to share­hold­ers, and it is al­so con­sid­er­ing “a tax-ef­fi­cient wind-down of the com­pa­ny,” the VC’s board an­nounced Thurs­day in a se­cu­ri­ties fil­ing.

The firm touts a dozen biotech com­pa­nies in its port­fo­lio, in­clud­ing Take­da-backed En­so­ma, Evom­mune, Au­ra Bio­sciences and Disc Med­i­cine, which went pub­lic last year via a re­verse merg­er with Gem­i­ni Ther­a­peu­tics. Evom­mune an­nounced in April it raised $50 mil­lion in a Se­ries B, with Ar­ix co-lead­ing the round.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER